Nomura Securities Starts Amgen (AMGN) at Neutral, $131 PT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks and yen struggle as tech troubles weigh
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Nomura Securities Starts Pharmacyclics (PCYC) at Buy
January 8, 2014 7:51 AM ESTNomura Securities initiates coverage on Pharmacyclics (NASDAQ: PCYC) with a Buy. PT $137.00.
Analyst Ian Somaiya comments: "Pharmacyclics is focused on the development and commercialization of small-molecule drugs for oncology and immunology. We expect the companys lead drug, Imbruvica, to transform the treatment... More
Nomura Securities Starts Neurocrine Bio. (NBIX) at Buy
January 8, 2014 7:44 AM ESTNomura Securities initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Buy. PT $23.00.
Analyst Ian Somaiya comments: "Neurocrine is focused on the development and commercialization of small molecule drugs for neurological and endocrine diseases. We expect positive Phase III data for lead drug elagolix... More
Nomura Securities Starts Gilead Sciences (GILD) at Buy; Top Biotech Stock Pick for 2014
January 8, 2014 7:43 AM ESTNomura Securities initiates coverage on Gilead Sciences (NASDAQ: GILD) with a Buy rating and $118 price target, naming the stock its biotech top stock pick for 2014.
"Set to dominant the Hepatitis C market through the 2011 acquisition of Pharmasset, which transformed the... More
